Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 50

1.

Prospective Cohort Study of Next-Generation Sequencing as a Diagnostic Modality for Unexplained Encephalitis in Children.

Haston JC, Rostad CA, Jerris RC, Milla SS, McCracken C, Pratt C, Wiley M, Prieto K, Palacios G, Shane AL, McElroy AK.

J Pediatric Infect Dis Soc. 2019 May 20. pii: piz032. doi: 10.1093/jpids/piz032. [Epub ahead of print]

PMID:
31107955
2.

Longitudinal Analysis of the Human B Cell Response to Ebola Virus Infection.

Davis CW, Jackson KJL, McElroy AK, Halfmann P, Huang J, Chennareddy C, Piper AE, Leung Y, Albariño CG, Crozier I, Ellebedy AH, Sidney J, Sette A, Yu T, Nielsen SCA, Goff AJ, Spiropoulou CF, Saphire EO, Cavet G, Kawaoka Y, Mehta AK, Glass PJ, Boyd SD, Ahmed R.

Cell. 2019 May 30;177(6):1566-1582.e17. doi: 10.1016/j.cell.2019.04.036. Epub 2019 May 16.

PMID:
31104840
3.

Ebola virus disease.

Malvy D, McElroy AK, de Clerck H, Günther S, van Griensven J.

Lancet. 2019 Mar 2;393(10174):936-948. doi: 10.1016/S0140-6736(18)33132-5. Epub 2019 Feb 15. Review. Erratum in: Lancet. 2019 May 18;393(10185):2038.

PMID:
30777297
4.

Characterization of Virus-specific Immune Response During Varicella Zoster Virus Encephalitis in a Young Adult.

Sullivan NL, Eberhardt CS, Wieland A, Akondy RS, Yi J, McElroy AK, Ahmed R.

Clin Infect Dis. 2019 Jul 2;69(2):348-351. doi: 10.1093/cid/ciy984.

PMID:
30668661
5.

Macrophage Activation Marker Soluble CD163 Associated with Fatal and Severe Ebola Virus Disease in Humans1.

McElroy AK, Shrivastava-Ranjan P, Harmon JR, Martines RB, Silva-Flannery L, Flietstra TD, Kraft CS, Mehta AK, Lyon GM, Varkey JB, Ribner BS, Nichol ST, Zaki SR, Spiropoulou CF.

Emerg Infect Dis. 2019 Feb;25(2):290-298. doi: 10.3201/eid2502.181326.

6.

Adaptive immune responses in humans during Nipah virus acute and convalescent phases of infection.

Arunkumar G, Devadiga S, McElroy AK, Prabhu S, Sheik S, Abdulmajeed J, Robin S, Sushama A, Jayaram A, Nittur S, Shakir M, Kumar KGS, Radhakrishnan C, Sakeena K, Vasudevan J, Reena KJ, Sarita RL, Klena JD, Spiropoulou CF, Laserson KF, Nichol ST.

Clin Infect Dis. 2019 Jan 7. doi: 10.1093/cid/ciz010. [Epub ahead of print]

PMID:
30615097
7.

CD4 T Cells, CD8 T Cells, and Monocytes Coordinate To Prevent Rift Valley Fever Virus Encephalitis.

Harmon JR, Spengler JR, Coleman-McCray JD, Nichol ST, Spiropoulou CF, McElroy AK.

J Virol. 2018 Nov 27;92(24). pii: e01270-18. doi: 10.1128/JVI.01270-18. Print 2018 Dec 15.

8.

Innate immune responses elicited by Sin Nombre virus or type I IFN agonists protect hamsters from lethal Andes virus infections.

Brocato RL, Wahl V, Hammerbeck CD, Josleyn MD, McElroy AK, Smith JM, Hooper JW.

J Gen Virol. 2018 Aug 1. doi: 10.1099/jgv.0.001131. [Epub ahead of print]

PMID:
30067171
9.

Human immune cell engraftment does not alter development of severe acute Rift Valley fever in mice.

Spengler JR, McElroy AK, Harmon JR, Coleman-McCray JD, Welch SR, Keck JG, Nichol ST, Spiropoulou CF.

PLoS One. 2018 Jul 20;13(7):e0201104. doi: 10.1371/journal.pone.0201104. eCollection 2018.

10.

Human Biomarkers of Outcome Following Rift Valley Fever Virus Infection.

McElroy AK, Harmon JR, Flietstra T, Nichol ST, Spiropoulou CF.

J Infect Dis. 2018 Oct 20;218(11):1847-1851. doi: 10.1093/infdis/jiy393.

PMID:
29955891
11.

Rift valley fever viral load correlates with the human inflammatory response and coagulation pathway abnormalities in humans with hemorrhagic manifestations.

de St Maurice A, Harmon J, Nyakarahuka L, Balinandi S, Tumusiime A, Kyondo J, Mulei S, Namutebi A, Knust B, Shoemaker T, Nichol ST, McElroy AK, Spiropoulou CF.

PLoS Negl Trop Dis. 2018 May 4;12(5):e0006460. doi: 10.1371/journal.pntd.0006460. eCollection 2018 May.

12.

Statins Suppress Ebola Virus Infectivity by Interfering with Glycoprotein Processing.

Shrivastava-Ranjan P, Flint M, Bergeron É, McElroy AK, Chatterjee P, Albariño CG, Nichol ST, Spiropoulou CF.

MBio. 2018 May 1;9(3). pii: e00660-18. doi: 10.1128/mBio.00660-18.

13.

Immune barriers of Ebola virus infection.

McElroy AK, Mühlberger E, Muñoz-Fontela C.

Curr Opin Virol. 2018 Feb;28:152-160. doi: 10.1016/j.coviro.2018.01.010. Epub 2018 Feb 16. Review.

14.

Encephalitis and Thalamic Injury From Neuroinvasive West Nile Virus in Children on Treatment for Acute Lymphoblastic Leukemia.

Farnaes L, Schiff D, McElroy AK, Coufal NG, Crawford JR, Cannavino C.

Pediatr Neurol. 2018 Mar;80:84-87. doi: 10.1016/j.pediatrneurol.2017.11.013. Epub 2017 Dec 2. No abstract available.

PMID:
29398166
15.

Whole Blood-Based Multiplex Immunoassays for the Evaluation of Human Biomarker Responses to Emerging Viruses in Resource-Limited Regions.

Harmon JR, Nichol ST, Spiropoulou CF, McElroy AK.

Viral Immunol. 2017 Nov;30(9):671-674. doi: 10.1089/vim.2017.0088. Epub 2017 Sep 22.

16.

A Case of Human Lassa Virus Infection With Robust Acute T-Cell Activation and Long-Term Virus-Specific T-Cell Responses.

McElroy AK, Akondy RS, Harmon JR, Ellebedy AH, Cannon D, Klena JD, Sidney J, Sette A, Mehta AK, Kraft CS, Lyon MG, Varkey JB, Ribner BS, Nichol ST, Spiropoulou CF.

J Infect Dis. 2017 Jun 15;215(12):1862-1872. doi: 10.1093/infdis/jix201.

17.

Ebola Virus Disease in Humans: Pathophysiology and Immunity.

Muñoz-Fontela C, McElroy AK.

Curr Top Microbiol Immunol. 2017;411:141-169. doi: 10.1007/82_2017_11. Review.

PMID:
28653186
18.

Crimean-Congo Hemorrhagic Fever in Humanized Mice Reveals Glial Cells as Primary Targets of Neurological Infection.

Spengler JR, Kelly Keating M, McElroy AK, Zivcec M, Coleman-McCray JD, Harmon JR, Bollweg BC, Goldsmith CS, Bergeron É, Keck JG, Zaki SR, Nichol ST, Spiropoulou CF.

J Infect Dis. 2017 Dec 12;216(11):1386-1397. doi: 10.1093/infdis/jix215.

19.

First Newborn Baby to Receive Experimental Therapies Survives Ebola Virus Disease.

Dörnemann J, Burzio C, Ronsse A, Sprecher A, De Clerck H, Van Herp M, Kolié MC, Yosifiva V, Caluwaerts S, McElroy AK, Antierens A.

J Infect Dis. 2017 Jan 15;215(2):171-174. doi: 10.1093/infdis/jiw493.

20.

Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination.

Ellebedy AH, Jackson KJ, Kissick HT, Nakaya HI, Davis CW, Roskin KM, McElroy AK, Oshansky CM, Elbein R, Thomas S, Lyon GM, Spiropoulou CF, Mehta AK, Thomas PG, Boyd SD, Ahmed R.

Nat Immunol. 2016 Oct;17(10):1226-34. doi: 10.1038/ni.3533. Epub 2016 Aug 15.

21.

Rift Valley fever virus: Unanswered questions.

Bird BH, McElroy AK.

Antiviral Res. 2016 Aug;132:274-80. doi: 10.1016/j.antiviral.2016.07.005. Epub 2016 Jul 9. Review.

PMID:
27400990
22.

Kinetic Analysis of Biomarkers in a Cohort of US Patients With Ebola Virus Disease.

McElroy AK, Harmon JR, Flietstra TD, Campbell S, Mehta AK, Kraft CS, Lyon MG, Varkey JB, Ribner BS, Kratochvil CJ, Iwen PC, Smith PW, Ahmed R, Nichol ST, Spiropoulou CF.

Clin Infect Dis. 2016 Aug 15;63(4):460-7. doi: 10.1093/cid/ciw334. Epub 2016 Jun 27. Erratum in: Clin Infect Dis. 2017 Aug 15;65(4):706.

23.

Ebola Virus Persistence in Semen of Male Survivors.

Uyeki TM, Erickson BR, Brown S, McElroy AK, Cannon D, Gibbons A, Sealy T, Kainulainen MH, Schuh AJ, Kraft CS, Mehta AK, Lyon GM 3rd, Varkey JB, Ribner BS, Ellison RT 3rd, Carmody E, Nau GJ, Spiropoulou C, Nichol ST, Ströher U.

Clin Infect Dis. 2016 Jun 15;62(12):1552-1555. doi: 10.1093/cid/ciw202. Epub 2016 Apr 3.

PMID:
27045122
24.

Relationship Between Ebola Virus Real-Time Quantitative Polymerase Chain Reaction-Based Threshold Cycle Value and Virus Isolation From Human Plasma.

Spengler JR, McElroy AK, Harmon JR, Ströher U, Nichol ST, Spiropoulou CF.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S346-9. doi: 10.1093/infdis/jiv187. Epub 2015 May 3.

25.

The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States.

Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, Varkey JB, Mehta AK, Lyon GM 3rd, Friedman-Moraco RJ, Marconi VC, Hill CE, Sullivan JN, Johnson DW, Lisco SJ, Mulligan MJ, Uyeki TM, McElroy AK, Sealy T, Campbell S, Spiropoulou C, Ströher U, Crozier I, Sacra R, Connor MJ Jr, Sueblinvong V, Franch HA, Smith PW, Ribner BS; Nebraska Biocontainment Unit and the Emory Serious Communicable Diseases Unit.

Clin Infect Dis. 2015 Aug 15;61(4):496-502. doi: 10.1093/cid/civ334. Epub 2015 Apr 22.

26.

Human Ebola virus infection results in substantial immune activation.

McElroy AK, Akondy RS, Davis CW, Ellebedy AH, Mehta AK, Kraft CS, Lyon GM, Ribner BS, Varkey J, Sidney J, Sette A, Campbell S, Ströher U, Damon I, Nichol ST, Spiropoulou CF, Ahmed R.

Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4719-24. doi: 10.1073/pnas.1502619112. Epub 2015 Mar 9.

27.

Biomarkers for understanding Ebola virus disease.

McElroy AK, Spiropoulou CF.

Biomark Med. 2014;8(9):1053-6. doi: 10.2217/bmm.14.75. No abstract available.

28.

Clinical care of two patients with Ebola virus disease in the United States.

Lyon GM, Mehta AK, Varkey JB, Brantly K, Plyler L, McElroy AK, Kraft CS, Towner JS, Spiropoulou C, Ströher U, Uyeki TM, Ribner BS; Emory Serious Communicable Diseases Unit.

N Engl J Med. 2014 Dec 18;371(25):2402-9. doi: 10.1056/NEJMoa1409838. Epub 2014 Nov 12.

29.

Von Willebrand factor is elevated in individuals infected with Sudan virus and is associated with adverse clinical outcomes.

McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Towner JS, Nichol ST, Spiropoulou CF.

Viral Immunol. 2015 Feb;28(1):71-3. doi: 10.1089/vim.2014.0072.

30.

Biomarker correlates of survival in pediatric patients with Ebola virus disease.

McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS, Spiropoulou CF.

Emerg Infect Dis. 2014 Oct;20(10):1683-90. doi: 10.3201/eid2010.140430.

31.

Marburgvirus resurgence in Kitaka Mine bat population after extermination attempts, Uganda.

Amman BR, Nyakarahuka L, McElroy AK, Dodd KA, Sealy TK, Schuh AJ, Shoemaker TR, Balinandi S, Atimnedi P, Kaboyo W, Nichol ST, Towner JS.

Emerg Infect Dis. 2014 Oct;20(10):1761-4. doi: 10.3201/eid2010.140696. No abstract available.

32.

Reply to Fedson.

McElroy AK, Spiropoulou CF.

J Infect Dis. 2015 Feb 15;211(4):662-3. doi: 10.1093/infdis/jiu475. Epub 2014 Aug 25. No abstract available.

33.

Rift valley Fever virus encephalitis is associated with an ineffective systemic immune response and activated T cell infiltration into the CNS in an immunocompetent mouse model.

Dodd KA, McElroy AK, Jones TL, Zaki SR, Nichol ST, Spiropoulou CF.

PLoS Negl Trop Dis. 2014 Jun 12;8(6):e2874. doi: 10.1371/journal.pntd.0002874. eCollection 2014 Jun.

34.

Ebola hemorrhagic Fever: novel biomarker correlates of clinical outcome.

McElroy AK, Erickson BR, Flietstra TD, Rollin PE, Nichol ST, Towner JS, Spiropoulou CF.

J Infect Dis. 2014 Aug 15;210(4):558-66. doi: 10.1093/infdis/jiu088. Epub 2014 Feb 12.

35.

Bacillary Angiomatosis in Patients With Cancer: A Pediatric Case Report and a Review of the Literature.

McElroy AK, Hilinski JA, Abramowsky CR, Jaffe R, Park SI, Shehata BM, Cooper TM.

J Pediatric Infect Dis Soc. 2013 Jun;2(2):175-8. doi: 10.1093/jpids/pis085. Epub 2012 Sep 18. No abstract available.

PMID:
26619465
36.

Rift Valley fever virus clearance and protection from neurologic disease are dependent on CD4+ T cell and virus-specific antibody responses.

Dodd KA, McElroy AK, Jones ME, Nichol ST, Spiropoulou CF.

J Virol. 2013 Jun;87(11):6161-71. doi: 10.1128/JVI.00337-13. Epub 2013 Mar 27.

37.

Bartonella henselae-mediated disease in solid organ transplant recipients: two pediatric cases and a literature review.

Rostad CA, McElroy AK, Hilinski JA, Thompson MP, Drew CP, Denison AM, Zaki SR, Mahle WT, Rogers J, Abramowsky CR, Shehata B.

Transpl Infect Dis. 2012 Oct;14(5):E71-81. doi: 10.1111/j.1399-3062.2012.00774.x. Epub 2012 Aug 3. Review.

PMID:
22862881
39.

Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep.

Bird BH, Maartens LH, Campbell S, Erasmus BJ, Erickson BR, Dodd KA, Spiropoulou CF, Cannon D, Drew CP, Knust B, McElroy AK, Khristova ML, Albariño CG, Nichol ST.

J Virol. 2011 Dec;85(24):12901-9. doi: 10.1128/JVI.06046-11. Epub 2011 Oct 5.

40.

Development of a RVFV ELISA that can distinguish infected from vaccinated animals.

McElroy AK, Albariño CG, Nichol ST.

Virol J. 2009 Aug 13;6:125. doi: 10.1186/1743-422X-6-125.

41.

Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus.

Spik K, Shurtleff A, McElroy AK, Guttieri MC, Hooper JW, SchmalJohn C.

Vaccine. 2006 May 22;24(21):4657-66. Epub 2005 Aug 22.

PMID:
16174542
42.

Identification of Dobrava, Hantaan, Seoul, and Puumala viruses by one-step real-time RT-PCR.

Aitichou M, Saleh SS, McElroy AK, Schmaljohn C, Ibrahim MS.

J Virol Methods. 2005 Mar;124(1-2):21-6. Epub 2004 Nov 25.

PMID:
15664046
44.

Andes virus M genome segment is not sufficient to confer the virulence associated with Andes virus in Syrian hamsters.

McElroy AK, Smith JM, Hooper JW, Schmaljohn CS.

Virology. 2004 Aug 15;326(1):130-9.

45.
46.

Andes virus infection of cynomolgus macaques.

McElroy AK, Bray M, Reed DS, Schmaljohn CS.

J Infect Dis. 2002 Dec 15;186(12):1706-12. Epub 2002 Nov 22.

PMID:
12447754
47.
49.

Exploitation of cellular signaling and regulatory pathways by human cytomegalovirus.

Fortunato EA, McElroy AK, Sanchez I, Spector DH.

Trends Microbiol. 2000 Mar;8(3):111-9. Review.

PMID:
10707064
50.

Nuclear-cytoplasmic shuttling of C-ABL tyrosine kinase.

Taagepera S, McDonald D, Loeb JE, Whitaker LL, McElroy AK, Wang JY, Hope TJ.

Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7457-62.

Supplemental Content

Loading ...
Support Center